However, MAS, secondary hemophagocytic lymphohistiocytosis followed by rheumatic diseases, occurs even in patients with s-JIA and AOSD receiving IL-1 and IL-6 inhibitors (63–67). This evidence concerns the gene IL6 and juvenile idiopathic arthritis.